ThinkGenetic, Inc.

ThinkGenetic, Inc. is a biotechnology firm focused on delivering advanced genetic testing solutions, facilitating the understanding of genetic conditions for individuals and healthcare providers. Founded in 2015 in Waynesboro, US, ThinkGenetic, Inc. specializes in genetic testing to inform health management.

The company was established by Dave Jacob and Dawn Laney. It has raised USD 1. 5 mn in Angel funding as of February 19, 2019, achieving a total amount raised of USD 1. 5 mn.

ThinkGenetic specializes in providing innovative genetic testing solutions aimed at empowering individuals and families in understanding genetic conditions. Their core offerings include a range of genetic testing services that help identify hereditary disease risks and inform personalized health management strategies. ThinkGenetic’s services are designed to enhance decision-making for patients and healthcare providers by providing detailed insights into genetic predispositions and potential health outcomes. The company primarily targets consumers, healthcare professionals, and genetic counselors, ensuring that end-users can access crucial genetic information in a comprehensible format.

Geographically, ThinkGenetic’s products and services are accessible in multiple markets, including North America and parts of Europe, positioning the company to serve a diverse client base across varying healthcare systems. ThinkGenetic generates revenue through a combination of direct-to-consumer sales and partnerships with healthcare providers. The company utilizes a subscription-based model for its genetic testing services, allowing users to gain ongoing access to significant updates and insights regarding their genetic profiles. Partnerships with healthcare organizations further facilitate the integration of ThinkGenetic’s services into clinical practice, enabling healthcare providers to offer genetic testing as part of their patient care protocols.

The business transactions often entail the provision of comprehensive genetic reports, which are accessed by consumers and healthcare professionals alike, thus enhancing the value proposition of ThinkGenetic’s flagship services. Specific pricing plans and product details are structured to cater to various market needs, ensuring that clients receive tailored services that align with their individual health management goals. Looking ahead, ThinkGenetic plans to launch new products designed to enhance its genetic testing capabilities and improve user experience. There are specific initiatives targeting expansion into additional markets, including Europe and Asia, by the end of 2023.

The recent Angel funding of USD 1. 5 mn raised in February 2019 will be utilized to support these product developments and market expansion efforts.